As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

treatment and risk management that have been made in 2024. The Alzheimer’s Association — a Chicago-based nonprofit committed ...

Before treatment, patients need a diagnosis confirmed ... based on a blood test as the enrolment criterion for dementia drug trials. That could pave the way for those blood tests, which look ...

Researchers at Nanyang Technological University in Singapore have identified a new “energy switch” in immune cells of the ...

Dementia with Lewy bodies (DLB ... health records of over 600,000 men who were taking different types of drug treatment for benign prostatic hyperplasia (BPH). Subjects were followed for an ...

Just 2.1 per cent of people with dementia undergo specialist investigations – such as having MRI or PET scans, which would be required for treatment with the breakthrough drugs lecanemab and ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...

Vitamin D also helps clear beta amyloid, a protein that plays a role in Alzheimer’s disease, Merrill points out. This is “the ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...